# Clinical trials recruiting in Louisiana: 885 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 885 trials recruiting or not yet recruiting with a site in Louisiana, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Louisiana: 885 rows for $44.25, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 17 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/louisiana

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 885
- Recruiting or not yet: 885
- Read on: November 19, 2026

## Trials

The 25 newest of 885, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07919678 | A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1) | Pfizer | Phase 3 | Recruiting | Obesity, Overweight, Osteoarthritis of the Knee | 656 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919678) |
| October 29, 2026 | NCT07903402 | AGU Registry and NHS | Sponsor not shown (see the record) | Observational | Recruiting | Aspartylglucosaminuria, Aspartylglucosamidase (AGA) Deficiency | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903402) |
| October 23, 2026 | NCT07891728 | A Multicenter Evaluation of SalivIQ™ Strep A for Detecting Group A Streptococcus From Saliva and Throat Swabs in Patients With Acute... | SalivIQ Diagnostics, Inc. | Observational | Recruiting | Streptococcal Pharyngitis, Group A Streptococcal Infection | 668 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891728) |
| October 20, 2026 | NCT07883564 | Improving Implementation of Guideline-Recommended LDL-C Management in High-Risk Cardiovascular Patients | Cardiology Consultants of Philadelphia | Observational | Not yet recruiting | ASCVD | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883564) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 19, 2026 | NCT07881432 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity | 2,115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881432) |
| October 13, 2026 | NCT07871513 | A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With... | AbbVie | Phase 2 | Recruiting | Upper Facial Lines, Glabellar Lines | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871513) |
| October 9, 2026 | NCT07867938 | A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Pulmonary Sarcoidosis | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867938) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |
| October 2, 2026 | NCT07855900 | SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose... | Boehringer Ingelheim | Phase 3 | Recruiting | Obesity | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855900) |
| October 2, 2026 | NCT07854782 | Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854782) |
| October 1, 2026 | NCT07851025 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced... | AstraZeneca | Phase 3 | Recruiting | Epithelial Ovarian Cancer | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851025) |
| September 30, 2026 | NCT07850050 | SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have... | Boehringer Ingelheim | Phase 3 | Recruiting | Obesity | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850050) |
| September 29, 2026 | NCT07848191 | Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis | Madrigal Pharmaceuticals, Inc. | Phase 4 | Recruiting | MASH - Metabolic Dysfunction-Associated Steatohepatitis | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848191) |
| September 29, 2026 | NCT07848178 | Roybal Via Habit Formation | Louisiana State University and A&M College | Not applicable | Not yet recruiting | Physical Inactivity, Sedentary Lifestlye | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848178) |
| September 29, 2026 | NCT07845487 | A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845487) |
| September 24, 2026 | NCT07837973 | Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss | Alveus Therapeutics, Inc. | Phase 2 | Recruiting | Overweight , Obesity, Adults | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837973) |
| September 21, 2026 | NCT07832292 | A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer | Janssen Research & Development, LLC | Phase 2 | Recruiting | Prostatic Neoplasms | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832292) |
| September 21, 2026 | NCT07830732 | A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A | Novo Nordisk A/S | Phase 3 | Recruiting | Haemophilia A | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830732) |
| September 18, 2026 | NCT07828613 | Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries | Johns Hopkins University | Not applicable | Not yet recruiting | Open Tibia Fracture, Open Dislocation of Ankle, Extremity Fracture Lower, Extremity Injuries Lower | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828613) |
| September 16, 2026 | NCT07822321 | Brexanolone Lifting Outcomes Of Moms | Lipocine Inc. | Phase 3 | Recruiting | Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression, Post-Natal... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822321) |
| September 15, 2026 | NCT07819435 | Phase 2/3 Efficacy and Safety of PP405 in Adult Males | Pelage Pharmaceuticals, Inc. | Phase 2/3 | Recruiting | Androgenetic Alopecia | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819435) |
| September 14, 2026 | NCT07816666 | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | AstraZeneca | Phase 3 | Recruiting | Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer... | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816666) |
| September 10, 2026 | NCT07812090 | A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema | BioAge Labs, Inc. | Phase 2 | Recruiting | Diabetic Macular Edema (DME) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812090) |
| September 8, 2026 | NCT07807163 | A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC | Bicara Therapeutics | Phase 2 | Recruiting | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807163) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| Ochsner Medical Center Jefferson | New Orleans | 56 |
| University Medical Center New Orleans | New Orleans | 55 |
| Ochsner Clinic Foundation | New Orleans | 49 |
| Pennington Biomedical Research Center | Baton Rouge | 31 |
| Our Lady of the Lake Physician Group | Baton Rouge | 31 |
| Mary Bird Perkins Cancer Center | Baton Rouge | 30 |
| LSU Health Baton Rouge-North Clinic | Baton Rouge | 28 |
| Children's Hospital New Orleans | New Orleans | 27 |
| East Jefferson General Hospital | Metairie | 25 |
| Louisiana State University Health Science Center | New Orleans | 21 |
| LSU Health Sciences Center at Shreveport | Shreveport | 20 |
| Tulane University School of Medicine | New Orleans | 18 |
| Tulane University | New Orleans | 17 |
| Tandem Clinical Research | Metairie | 17 |
| Louisiana Hematology Oncology Associates LLC | Baton Rouge | 16 |
| Cardiovascular Institute of the South | Houma | 16 |
| Louisiana State University | Baton Rouge | 15 |
| Ochsner Medical Center | New Orleans | 14 |
| Ochsner LSU Health Monroe Medical Center | Monroe | 13 |
| West Jefferson Medical Center | Marrero | 13 |
| Louisiana State University Health Sciences Center | New Orleans | 12 |
| Ochsner Hematology Oncology North Shore - Covington (West Region) | Covington | 12 |
| LSU Healthcare Network / Metairie Multi-Specialty Clinic | Metairie | 11 |
| Mary Bird Perkins Cancer Center - Metairie | Metairie | 10 |
| University Medical Center | New Orleans | 9 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 2 |
| Phase 1 | 25 |
| Phase 1/2 | 36 |
| Phase 2 | 150 |
| Phase 2/3 | 26 |
| Phase 3 | 356 |
| Phase 4 | 33 |
| Not applicable | 142 |
| Observational | 115 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Obesity | 42 |
| Carcinoma, Non-Small-Cell Lung | 29 |
| Overweight | 26 |
| Breast Neoplasms | 26 |
| Prostatic Neoplasms | 24 |
| Heart Failure | 21 |
| Neoplasms | 20 |
| Neoplasm Metastasis | 20 |
| Colorectal Neoplasms | 20 |
| Diabetes Mellitus, Type 2 | 19 |
| Ovarian Neoplasms | 17 |
| Endometrial Neoplasms | 17 |
| Leukemia, Myeloid, Acute | 15 |
| Lung Neoplasms | 15 |
| Cardiovascular Diseases | 14 |
| Urinary Bladder Neoplasms | 14 |
| Hypertension | 13 |
| Pancreatic Neoplasms | 13 |
| Colitis, Ulcerative | 12 |
| Atrial Fibrillation | 12 |
| Crohn Disease | 12 |
| Multiple Myeloma | 12 |
| Fallopian Tube Neoplasms | 11 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 11 |
| Non-alcoholic Fatty Liver Disease | 11 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 47 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 38 |
| Pennington Biomedical Research Center | 28 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 28 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 19 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 19 |
| Tulane University | 18 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 17 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 17 |
| Children's Oncology Group | 17 |
| NRG Oncology | 15 |
| Alliance for Clinical Trials in Oncology | 15 |
| SWOG Cancer Research Network | 14 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 13 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 12 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 12 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 11 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 11 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 10 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 9 |
| Louisiana State University Health Sciences Center in New Orleans | 9 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 7 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 7 |
| ECOG-ACRIN Cancer Research Group | 7 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 6 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Louisiana

- [Electronic equipment suppliers in Louisiana, United States](https://specstream.ai/data/businesses/electronic-equipment-suppliers/louisiana-united-states)
- [Environmental testing companies in Louisiana, United States](https://specstream.ai/data/businesses/environmental-testing-companies/louisiana-united-states)
- [Fast food restaurants in Louisiana, United States](https://specstream.ai/data/businesses/fast-food-restaurants/louisiana-united-states)
- [Food and beverage distributors in Louisiana, United States](https://specstream.ai/data/businesses/food-and-beverage-distributors/louisiana-united-states)
- [General dentistry practices in Louisiana, United States](https://specstream.ai/data/businesses/general-dentistry-practices/louisiana-united-states)
- [Home builders in Louisiana, United States](https://specstream.ai/data/businesses/home-builders/louisiana-united-states)
